Biggest stock movers Monday: ITCI, and SAGE

More on related stocks:

• Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move
• CNS Drug Development: Same As It Ever Was
• Seeking Alpha | January 13, 2025

Johnson & Johnson in talks to acquire Intra-Cellular - Bloomberg

More on Intra-Cellular Therapies

• Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move
• Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript
• Seeking Alpha | January 12, 2025

Johnson & Johnson exploring takeover of Intra-Cellular - Bloomberg

More on Intra-Cellular Therapies

• Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move
• Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript
• Seeking Alpha | January 12, 2025

RBC buyers of Intra-Cellular after ‘more favorable-than-expected’ settlement

After Intra-Cellular Therapies (ITCI) announced that it has entered into a settlement agreement with Sandoz (SDZNY) resolving patent litigation related to Intra-Cellular Therapies’ product Caplyta, RBC Capital notes this makes Sandoz the first of the seven ANDA filers to reach a deal. More favorable-than-expected terms for first generic lumateperone settlement bode well for Intra-Cellular’s ability to maintain Caplyta revenue durability, says the firm, which “would be buyers into strength.” RBC

Yahoo | January 11, 2025

Intra-Cellular Therapies Stock Soars 19% After Securing Major Patent Victory Over Sandoz

Landmark settlement extends CAPLYTA's market exclusivity until 2040, fueling investor confidence and Wall Street buzz.

Yahoo | January 10, 2025

Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz

BEDMINSTER, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Sandoz Inc. (Sandoz) resolving patent litigation related to Intra-Cellular Therapies’ product CAPLYTA® (lumateperone). The litigation, which is pending in the U.S. District Court for the District

Yahoo | January 10, 2025

Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BEDMINSTER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT in San Francisco, CA. The live and archived webcast can be acc

Yahoo | January 6, 2025

When Will Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Turn A Profit?

With the business potentially at an important milestone, we thought we'd take a closer look at Intra-Cellular...

Yahoo | December 28, 2024

Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting

Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder Data shows robust remission and response efficacy rates in patients taking CAPLYTA Robust improvements in anxiety symptoms were also observed in patients taking CAPLYTA as measured by the Generalized Anxiety Disorder Questionnaire (GAD-7) Pooled safety and tolerability data from Studies 501 and 502 show

Yahoo | December 11, 2024

ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD

Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants.

Yahoo | December 4, 2024